Korea State R&D Fund Seeks Continuity To Enable Seamless Support

CEO Urges Post-2030 Renewal

The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.

KDDF CEO Yeong Min Park — South Korean R&D fund urges renewal as its support focuses on new modalities, novel targets (Jung Won Shin)

With the state-run Korea Drug Development Fund (KDDF), which plays a key role in providing R&D support to the country’s biopharma industry, already midway through its current 10-year term, the fund is stressing the need to raise its budget and ensure the continuity of time-limited projects to prevent disruptions.

The KDDF, a consortium of three South Korean government ministries (Health and Welfare, Trade, Industry and Energy, and Science and ICT), was established in 2011 to foster drug development programs nationally and provides assistance up to the Phase II stage

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

14 May 2025

• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

13 May 2025

• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

02 May 2025

• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.